WORLDREMIT
14.9.2020 13:11:06 CEST | Business Wire | Press release
Lonestar Cell MTN, Liberia’s leading GSM and Mobile Financial Services company, has partnered with WorldRemit to make it possible for Mobile Money customers to now receive international remittances straight to their Lonestar Cell MTN Mobile Money accounts, free of charge.
This service presents the exciting prospect for the Liberian community to receive seamless international remittances from their family and friends, anywhere in Europe, Canada and the USA.
Now, with over 7,000 Lonestar Cell MTN cashpoint locations across Liberia, the service eliminates the stress, risks and long queues in banking halls associated with receiving remittances sent by loved ones. In addition to the MoMo services which has a vast and rapidly expanding MoMo ecosystem, using MoMo for international remittances and daily financial transactions makes life easier, safer and more convenient.
Christopher Ssali, Acting General Manager of Lonestar Cell MTN Mobile Money, said, “Liberians can now receive international financial remittances from family and friends in Europe, Canada and the USA more easily and safely. We have seen how resilient the people of Liberia truly are and we are very proud to be at the forefront of innovative technologies and partnerships which can help Liberians live convenient lives. Our partnership with WorldRemit does just that. Our MoMo ecosystem has grown so customers can use the money they receive to pay bills, buy goods, and pay for the services they need with Mobile Money. We are excited about this because it makes our customers lives easier and we are supporting the government’s aim for a cashless digital economy and financial inclusion.”
Awa Gueye Ba, Head of Francophone West & Central Africa at WorldRemit, remarked that this partnership with Lonestar Cell MTN provides increased opportunities for customers to connect with their loved ones and receive convenient money transfers. “The MoMo service is one of the most demanded services in Liberia and we are excited about this collaboration with MTN Liberia, as it will allow users to send remittances 24/7 from the WorldRemit website or mobile app and receive directly to their MTN Mobile Money accounts. The partnership will further strengthen the efforts of the Central Bank of Liberia in focusing on diverse means of delivering financial services to the rural community sector of the population and integrating them into the formal economy.
Providing our customers with safe, convenient and fast means to receive money is an important step towards WorldRemit’s ambition to support customers, in the shift towards the digital economy.”
Customers who receive money can conveniently cashout, pay goods and services, or transfer the money to their friends and family at the prevailing standard Mobile Money fees. Customers who are not on MTN Mobile Money can join easily. Sign up is free. All they need to do is visit any Lonestar Cell MTN service center or registered MoMo agent with a valid identification card and fill out an application form.
We are #GoodTogether .
About Lonestar Cell MTN/MTN Liberia
Lonestar Cell MTN/MTN Liberia, Liberia’s leading telecommunications provider, was founded in 2001. We are a technology-based company with a focus on winning in everything we do while demonstrating consistency in innovation to meet our unique customer needs. We are a subsidiary of MTN, a leading international telecommunications groups operating in 21 countries across Africa and the Middle East.
For more information, please visit www.lonestarcell.com
About WorldRemit
WorldRemit is a leading global payments company. We disrupted an industry previously dominated by offline legacy players by taking international money transfers online - making them safer, faster and lower-cost. We currently send from 50 to 150 countries, operate in 6,500 money transfer corridors worldwide and employ over 1,100 people globally.
On the sending side WorldRemit is 100% digital (cashless), increasing convenience and enhancing security. For those receiving money, the company offers a wide range of options including bank deposit, cash collection, mobile airtime top-up and mobile money.
Backed by Accel, TCV and Leapfrog – WorldRemit’s headquarters are in London, United Kingdom with regional offices in the United States, Canada, Australia, New Zealand, Hong Kong, Singapore, Malaysia, the Philippines, South Africa, Somaliland, Uganda, Kenya, Rwanda, Tanzania, Zimbabwe and Belgium.
For more information visit www.worldremit.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005440/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom